IP Library › Granted Patent US 9,605,250
Granted Patent B2
US 9,605,250 · App. 14/111,531 · Granted Mar 28, 2017

Chimeric antibacterial polypeptides

Inventors: Chemira B. Appaiah (Bangalaore, IN); Sriram Padmanabhan (Bangalaore, IN); R. Sanjeev Saravanan (Bangalaore, IN); Bharathi Sriram (Bangalaore, IN)
Assignee: Gangagen, Inc.
C12N9/2462C07K14/005C07K14/47C07K14/4742C12N1/06C12N9/24C12N9/48C12N15/62A61K38/00C07K2319/03C12N2795/00022C12N2795/00033C12N2795/10122C12N2795/10133C12N2795/10322C12N2795/10333
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,605,250
App. No.
14/111,531
Granted
Mar 28, 2017
Kind
B2
Abstract

Provided herein are antibacterial compositions and methods of making and using the compositions.

Claims (8)

1. A chimeric polypeptide comprising a muralytic domain (MD) from a virion-associated muralytic enzyme, wherein the MD comprises a sequence at least 90% identical to amino acids 683-898 of SEQ ID NO:2 and is capable of lysing chloroform-treated Pseudomonas aeruginosa bacteria and a membrane traversing domain (MTD) segment, wherein the segment comprises a sequence at least 80% identical to amino acids 16-39 of SEQ ID NO:4 and is capable of traversing the outer membrane of Pseudomonas aeruginosa bacteria.

2. The chimeric polypeptide of claim 1 , which comprises a sequence having at least 90% identity to a sequence selected from: SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO: 13.

3. The chimeric polypeptide of claim 2 , wherein the chimeric polypeptide comprises SEQ ID NO: 9.

4. The chimeric polypeptide of claim 2 , wherein the chimeric polypeptide comprises SEQ ID NO: 11.

5. The chimeric polypeptide of claim 2 , wherein the chimeric polypeptide comprises SEQ ID NO: 13.

6. The chimeric polypeptide of claim 1 , wherein the chimeric polypeptide is attached to polyethylene glycol.

7. A pharmaceutical composition comprising the chimeric polypeptide of claim 1 and a pharmaceutically acceptable excipient.

8. An antibacterial formulation comprising the chimeric polypeptide of claim 1 and an agent that reduces oxidation.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2020
From: GANGAGEN, INC.
To: BACTOCLEAR HOLDINGS PTE. LTD.
Reel/Frame 052603/0390 →
RELEASE OF SECURITY INTEREST Recorded Jan 14, 2020
From: ATEL VENTURES, INC.
To: GANGAGEN, INC.
Reel/Frame 051507/0381 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2020
From: GANGAGEN, INC.
To: BACTOCLEAR HOLDINGS PTE. LTD.
Reel/Frame 051499/0244 →
SECURITY INTEREST Recorded Jul 26, 2018
From: GANGAGEN, INC.
To: ATEL VENTURES, INC.
Reel/Frame 046475/0531 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2013
From: APPAIAH, C.B.; PADMANABHAN, SRIRAM; SARAVANAN, R. SANJEEV; SRIRAM, BHARATHI
To: GANGAGEN, INC.
Reel/Frame 031627/0889 →
Priority Claims (1)
IN 1277/CHE/2011 · Apr 12, 2011 · national
Continuity (1)
Related Publication 20140050713A1 · Feb 20, 2014